Literature DB >> 20844956

Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS.

Mohamad R Al Sibae1, Mitchell S Cappell.   

Abstract

BACKGROUND: To systematically review literature on use of model for end-stage liver disease (MELD) score to determine severity and prognosis of liver disease in various clinical situations and to evaluate its use in decisions regarding therapeutic interventions.
METHODS: Computerized literature searches using key medical terms; review of authors' extensive files on this subject; and personal clinical experience.
RESULTS: The MELD score, a prospectively developed and validated scale for severity of end-stage liver disease, utilizes serum bilirubin, serum creatinine, and international normalized ratio to predict mortality in cirrhotic patients. It has proven clinically useful in increasingly varied clinical situations. The United Network for Organ Sharing uses MELD scores, with bonus points assigned for hepatocellular cancer, to prioritize allocation of deceased donor livers for liver transplantation. This work reviews recent data demonstrating that MELD scores relatively accurately predict mortality in patients with variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, and acute liver failure, as well as assess risks of non-liver transplantation surgery or transjugular intrahepatic portosystemic shunts in cirrhotic patients. MELD scores fail to predict mortality in about 15% of patients with end-stage liver disease. Incorporation of additional parameters, including serum sodium level, serum albumin level, glucose intolerance, or APACHE II score, may potentially improve prognostic accuracy.
CONCLUSIONS: MELD scores relatively accurately assess severity of liver disease and prognosis in patients with advanced liver disease in general, and in patients with individual complications of liver disease. It is useful in making decisions on potential therapies. Incorporating additional parameters may further improve its prognostic accuracy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20844956     DOI: 10.1007/s10620-010-1390-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  60 in total

1.  Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death.

Authors:  Douglas M Heuman; Souheil G Abou-Assi; Adil Habib; Leslie M Williams; R Todd Stravitz; Arun J Sanyal; Robert A Fisher; Anastasios A Mihas
Journal:  Hepatology       Date:  2004-10       Impact factor: 17.425

Review 2.  Prediction of survival for patients with fulminant hepatic failure.

Authors:  James Neuberger
Journal:  Hepatology       Date:  2005-01       Impact factor: 17.425

3.  Risk scores in cirrhotic patients: From non-transplant surgery to transplantation and back.

Authors:  François Durand
Journal:  J Hepatol       Date:  2006-01-04       Impact factor: 25.083

4.  Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis.

Authors:  C-Y Hsu; H-C Lin; Y-H Huang; C-W Su; F-Y Lee; T-I Huo; P-C Lee; J-Y Lee; S-D Lee
Journal:  Dig Liver Dis       Date:  2010-02       Impact factor: 4.088

Review 5.  Prognostic models in chronic liver disease: validity, usefulness and future role.

Authors:  E Christensen
Journal:  J Hepatol       Date:  1997-06       Impact factor: 25.083

6.  Combined MELD and blood lipid level in evaluating the prognosis of decompensated cirrhosis.

Authors:  Ming Jiang; Fei Liu; Wu-Jun Xiong; Lan Zhong; Wen Xu; Fei Xu; Yan-Bing Liu
Journal:  World J Gastroenterol       Date:  2010-03-21       Impact factor: 5.742

Review 7.  Surgery in the patient with liver disease.

Authors:  T Patel
Journal:  Mayo Clin Proc       Date:  1999-06       Impact factor: 7.616

8.  Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation.

Authors:  Maria-Carlota Londoño; Mónica Guevara; Antoni Rimola; Miquel Navasa; Pilar Taurà; Antoni Mas; Juan-Carlos García-Valdecasas; Vicente Arroyo; Pere Ginès
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

9.  Prognostic significance of diabetes in patients with cirrhosis.

Authors:  G Bianchi; G Marchesini; M Zoli; E Bugianesi; A Fabbri; E Pisi
Journal:  Hepatology       Date:  1994-07       Impact factor: 17.425

10.  MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients.

Authors:  Walter K Kremers; Marrije van IJperen; W Ray Kim; Richard B Freeman; Ann M Harper; Patrick S Kamath; Russell H Wiesner
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

View more
  33 in total

Review 1.  Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options.

Authors:  Brian Erly; William D Carey; Baljendra Kapoor; J Mark McKinney; Mathew Tam; Weiping Wang
Journal:  Semin Intervent Radiol       Date:  2015-12       Impact factor: 1.513

2.  Three-dimensional conformal radiotherapy for locally advanced hepatocellular carcinoma with portal vein tumour thrombosis: evaluating effectiveness of the model for end-stage liver disease (MELD) score compared with the Child-Pugh classification.

Authors:  Eiichiro Okazaki; Akira Yamamoto; Norifumi Nishida; Masao Hamuro; Ryo Ogino; Masako Hosono; Yasuhiko Shimatani; Shinichi Tsutsumi; Shinichi Hamamoto; Etsuji Sohgawa; Atsushi Jogo; Yukio Miki
Journal:  Br J Radiol       Date:  2016-05-10       Impact factor: 3.039

3.  Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis.

Authors:  Elliot B Tapper; Daniel Finkelstein; Murray A Mittleman; Gail Piatkowski; Michelle Lai
Journal:  Hepatology       Date:  2015-04-28       Impact factor: 17.425

4.  Clearing the Confusion over Hepatic Encephalopathy After TIPS Creation: Incidence, Prognostic Factors, and Clinical Outcomes.

Authors:  Leigh C Casadaban; Ahmad Parvinian; Jeet Minocha; Janesh Lakhoo; Christopher W Grant; Charles E Ray; M Grace Knuttinen; James T Bui; Ron C Gaba
Journal:  Dig Dis Sci       Date:  2014-10-15       Impact factor: 3.199

Review 5.  Therapy for alcoholic liver disease.

Authors:  Maryconi M Jaurigue; Mitchell S Cappell
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

6.  Development of an automated phenotyping algorithm for hepatorenal syndrome.

Authors:  Jejo D Koola; Sharon E Davis; Omar Al-Nimri; Sharidan K Parr; Daniel Fabbri; Bradley A Malin; Samuel B Ho; Michael E Matheny
Journal:  J Biomed Inform       Date:  2018-03-09       Impact factor: 6.317

7.  Predictors of a variceal source among patients presenting with upper gastrointestinal bleeding.

Authors:  Ahmad Alharbi; Majid Almadi; Alan Barkun; Myriam Martel
Journal:  Can J Gastroenterol       Date:  2012-04       Impact factor: 3.522

8.  Association of AKI with mortality and complications in hospitalized patients with cirrhosis.

Authors:  Justin M Belcher; Guadalupe Garcia-Tsao; Arun J Sanyal; Harjit Bhogal; Joseph K Lim; Naheed Ansari; Steven G Coca; Chirag R Parikh
Journal:  Hepatology       Date:  2012-12-06       Impact factor: 17.425

9.  Ascites Neutrophil Gelatinase-Associated Lipocalin Identifies Spontaneous Bacterial Peritonitis and Predicts Mortality in Hospitalized Patients with Cirrhosis.

Authors:  Giuseppe Cullaro; Grace Kim; Marcus R Pereira; Robert S Brown; Elizabeth C Verna
Journal:  Dig Dis Sci       Date:  2017-11-02       Impact factor: 3.199

10.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.

Authors:  Arun J Sanyal; Scott L Friedman; Arthur J McCullough; Lara Dimick-Santos
Journal:  Hepatology       Date:  2015-03-19       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.